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Abstract
Background and aims: Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) is characterized by
localized, non-pitting, and transient swelling of submucosal or subcutaneous region. Human fetuin-A is a
multifunctional glycoprotein that belongs to the proteinase inhibitor cystatin superfamily and has structural
similarities to the high molecular weight kininogen. Fetuin-A is also known a negative acute phase reactant with
anti-inflammatory characteristics. In this study we aimed to determine serum fetuin-A, C-reactive protein (CRP) and
tumor necrosis factor alpha (TNFα) concentrations in patients with C1-INH-HAE during symptom-free period and
during attacks and compare them to those of healthy controls. Further we analyzed possible relationship among
these parameters as well as D-dimer levels which was known as marker of HAE attacks.
Patients and methods: Serum samples of 25 C1-INH-HAE patients (8 men, 17 women, age: 33.1 ± 6.9 years, mean
± SD) were compared to 25 healthy controls (15 men, 10 women, age: 32.5 ± 7.8 years). Serum fetuin-A and TNFα
concentrations were determined by ELISA, CRP and D-dimer by turbidimetry.
Results: Compared to healthy controls patients with C1-INH-HAE in the symptom-free period had significantly
decreased serum fetuin-A 258 μg/ml (224–285) vs. 293 μg/ml (263–329), (median (25–75% percentiles, p = 0.035)
and TNFα 2.53 ng/ml (1.70–2.83) vs. 3.47 ng/ml (2.92–4.18, p = 0.0008) concentrations. During HAE attacks fetuin-A
levels increased from 258 (224–285) μg/ml to 287 (261–317) μg/ml (p = 0.021). TNFα and CRP levels did not change
significantly. We found no significant correlation among fetuin-A CRP, TNFα and D-dimer levels in any of these
three groups.
Conclusions: Patients with C1-INH-HAE have decreased serum fetuin-A concentrations during the symptom-free
period. Given the anti-inflammatory properties of fetuin-A, the increase of its levels may contribute to the counter-
regulation of edema formation during C1-INH-HAE attacks.
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Introduction
Hereditary angioedema with C1-inhibitor (C1-INH) defi-
ciency (C1-INH-HAE) is a rare autosomal dominant dis-
order (estimated prevalence: 1:150,000 to 1:10,000) [1]
characterized by the decreased of C1 inhibitor (C1-INH)
activity. In 80% of the cases the C1-INH molecule has
low antigenic levels (C1-INH-HAE Type I), in 20%
C1-INH is present and can have high antigen levels but
with low function (C1-INH-HAE Type II). C1-INH reg-
ulates the complement, contact, coagulation, and fi-
brinolytic plasma enzyme cascades. The deficiency of
C1-INH leads to the uncontrolled, spontaneous activa-
tion of these plasma enzyme systems. Contact-kinin sys-
tem activation results in the release of the vasoactive
mediator bradykinin from high molecular weight kinino-
gen (HMWK), which causes vasodilation, increased
vascular permeability, and plasma leakage into the extra-
cellular space, leading to edema formation [2–4]. The
HAE attacks may involve the extremities, the face, the
trunk genitals, and submucosal tissues in the gastro-
intestinal tract and upper airways. In the gastrointestinal
tract, angioedema may mimic an abdominal catastrophe,
whereas in the upper airways, it may cause obstruction
leading to suffocation [5]. Occurrence of HAE attacks is
unpredictable, but some trigger factors, including infec-
tion, mechanical trauma, mental stress, hormonal changes,
drugs (estrogens and angiotensin converting enzyme in-
hibitors) can be explored in a proportion of patients [6, 7].
Recently, some evidences tend to confirm a relation-
ship between HAE and atherosclerosis, as well. In this
respect, Demirtürk et al. observed decreased coronary
blood flow reserve pointing to increased risk of athero-
sclerosis [8]. Moreover, in their latest paper Firinu et al.
observed impaired finger plethysmography values and
asymmetric dimethylarginine levels strongly suggesting
endothelial dysfunction in this disease [9].
Bradykinin-mediated angioedema should be distin-
guished from histaminergic angioedema. The latter is
characterized by the type I immunoreaction, rapid (24 h)
symptom development, frequent association with itching
urticaria, and responsiveness to antihistamines, cortico-
steroids or epinephrine. Bradykinin-mediated angio-
edema has a more protracted symptom development
(typically 3–5 days), does not present with pruritus but
can be painful, and does not react to the drugs men-
tioned above. The acute HAE attacks are terminated by
C1-INH concentrate and tranexamic acid and danazol
are established for prophylaxis.
Human fetuin-A (formerly called α2HS-glycoprotein)
is a multifunctional glycoprotein which is secreted al-
most exclusively by the liver parenchymal cells in
adulthood [10]. Early studies have shown that fetuin-A acts
as a negative acute phase protein [11], decreases the
phytohemagglutinin-induced lymphoblastic transformation
[12], increases opsonization and phagocytosis [13, 14] and
regulates superoxide release of neutrophil granulocytes
[15].
In addition fetuin-A is a mineral chaperone [16], at-
taches to hydroxyapatite crystals and inhibits calcifica-
tion both in vitro and in vivo [15, 17]. It accumulates is
bone being the most abundant non-collagenous protein
in bone and dentin [10, 18]. The role of fetuin-A has
also been established in the development of obesity [19,
20], insulin resistance [21], metabolic syndrome [20, 22],
adipocyte dysfunction [23], fatty liver [21], and type 2
diabetes [24, 25].
Probably due to impaired inhibition of vascular calcifi-
cation low serum fetuin-A concentration has been asso-
ciated with increased cardiovascular risk in patients
without diabetes, as well [26, 27].
Fetuin-A is a member of the cystatin superfamily [28, 29].
Cystatins are proteinase inhibitors. This superfamily has
members with similar tandem repeats, one in cystatin C,
two in fetuin-A and fetuin B, and three in the kininogens
[29]. In fetuin-A the proline-rich carboxyl-terminal region
of the A-chain displays sequence similarity to collagens
and the collagen-like domains of complement component
C1q [30].
The serum fetuin-A has not been investigated in
C1-INH-HAE; however, these structural similarities of
fetuin-A with C1q and HMWK, which have important
role in the pathomechanism of C1-INH-HAE and as
fetuin-A is a negative acute phase protein may influence
the development of HAE attacks. Therefore, we aimed
to determine serum concentrations of fetuin-A, and
other inflammatory markers such as C-reactive protein
(CRP) and tumor necrosis factor-α (TNFα) in patients
with C1-INH-HAE during both symptom-free period
and attacks and compare them to those of healthy
controls.
Patients and methods
Patients and controls
Twenty-five C1-INH-HAE patients (8 men, 17 women,
age: 33.1 ± 6.9 years, mean ± SD), 20 with type I and 5 pa-
tients with type II of C1-INH-HAE, were enrolled to our
study. The diagnosis of C1-INH-HAE was established by
pedigree-analysis, as well as by the evaluation of the clin-
ical manifestations and complement parameters (low anti-
genic and functional levels of C1-INH, low level of C4 and
normal level of C1q). Ten patients received long-term
prophylaxis, 9 of them were on long-term danazol, and
one of them was on tranexamic acid. The remaining 15
patients did not receive long-term prophylaxis. For acute
treatment of HAE attacks patients received human
plasma-derived C1-INH concentrate (Berinert®, CSL
Behring, Marburg, Germany) when it was necessary. The
location of the HAE attack, the onset of edematous
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symptoms as well as the time from onset to acute
treatment were recorded in the Hungarian HAE Registry.
Twelve HAE attacks occurred submucosally (7 in abdom-
inal viscera, 3 in the upper airways, 2 in other localization),
12 subcutaneously, and 1 in mixed locations.
The control group consisted of 25 healthy volunteers
(10 men, 15 women, age: 32.5 ± 7.8 years), referred for
routine medical evaluation. The healthy controls did not
have any known disease, nor they received medicinal
products at the time of blood sampling. C1-INH defi-
ciency was excluded by complement testing. The
C1-INH-HAE patients and the controls were not statis-
tically different as regards age and gender distribution.
Blood sampling
Peripheral blood samples were obtained from patients
with C1-INH-HAE both during symptom-free periods
and during attacks (before acute treatment). “Symptom--
free” samples were obtained during the annual control
visits in the Hungarian Angioedema Center. “During at-
tack” samples were obtained prior to acute treatment,
within 6 h after the onset of the edematous symptoms.
None of the patients had any clinical manifestations
suggestive of an acute infection during the HAE at-
tack. Peripheral blood samples were drawn also from
healthy subjects. According to standard procedures
native serum (after clotting completed), EDTA- and
citrate-anticoagulated plasma (immediately after blood
taking) were separated by centrifugation at 3500 rpm
for 10min. Thereafter, the obtained serum, EDTA and cit-
rate plasma samples were then stored below − 70 °C until
processing.
Methods
All analyzed parameters were determined using the same
unthawed aliquot from each subject, and each assay was
performed on aliquots thawed for the same length of time.
Plasma fetuin-A and TNFα concentrations were determined
by sandwich-type ELISA (BioVendor, Czech Republic, and
Thermofisher Scientific Inc., Waltham, USA, respectively),
according to the manufacturers’ instructions. Levels of CRP
were determined in EDTA-plasma samples using a chemis-
try analyzer (Beckman Coulter Inc., California, USA).
The determination of D-dimer concentration was per-
formed in citrated plasma by latex agglutination immu-
noturbidimetry on a COAG XL coagulometer (Diagon
Ltd., Budapest, Hungary) using the Dia-D-DIMER test
(Diagon Ltd., Budapest, Hungary).
Statistical analysis
The statistical analysis was performed by the SPSS 23
version (SPSS, Chicago, IL, USA). We used nonparamet-
ric tests throughout the analysis. All the statistical ana-
lyses were two-tailed, and p < 0.05 was considered to
represent a significant difference, or correlation.
Results
During the symptom-free period C1-INH-HAE patients
had significantly lower fetuin-A and TNFα levels com-
pared to healthy controls. CRP levels did not show
marked differences compared these two groups (Table 1).
In “during attack” samples of C1-INH-HAE patients
fetuin-A levels were significantly higher compared to the
symptom-free period of the same patients. In contrast,
CRP and TNFα levels were comparable in samples ob-
tained from symptom-free and from during attack pe-
riods of the same patient. D dimer levels significantly
rose in patients during attacks than in the symptom-free
period of the same patients and were also higher com-
pared to the healthy control group.
We divided our patients according to the localization of
HAE attack (Table 2). Dividing the measured parameters
regarding attack location we found elevated fetuin-A
levels only during subcutaneous attacks compared to
symptom-free period: 295 (260–325) μg/ml vs. 254
(200–273) μg/ml, p = 0.033; median (25–75 percentile)
Table 1 Serum fetuin-A, CRP and TNFα concentrations in patients with C1-INH-HAE and healthy controls
Symptom-free phase Attack Healthy controls p1 p2 p3
Fetuin-A, μg/ml 258 287 293 0.035 0.021 0.945
(224–285) (261–317) (263–329)
CRP, mg/l 1.25 3.57 1.95 0.303 0.247 0.528
(0.77–4.75) (0.93–4.73) (1.16–3.91)
TNFα, ng/ml 2.53 2.73 3.47 0.0008 0.207 0.166
(1.70–2.83) (1.80–3.71) (2.92–4.18)
D-dimer, μg/ml 0.52 2.44 0.42 0.405 0.023 0.006
(0.22–1.26) (0.67–5.36) (0.36–0.85)
Values in median (25–75) percentiles
p1: symptom-free phase vs. healthy controls, Mann-Whitney test
p2: symptom-free phase vs. attack, Wilcoxon test
p3: attack vs. healthy controls, Mann-Whitney test
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(n = 12), whereas during submucosal attacks (abdominal
plus upper airways localization) fetuin-A levels the differ-
ence between “during HAE attacks” and “symptom-free”
samples was not statistically significant: 286 (262–320)
ug/ml vs. 265 (241–297) ug/ml, n = 12, p = 0.308.
We did not observe significant differences in fetuin-A,
CRP or TNFα levels between subcutaneous and sub-
mucosal groups. Comparison of serum fetuin-A, CRP
and TNFα concentrations during HAE attacks with
healthy controls showed no significant differences.
We found no significant correlations among fetuin-A,
CRP,TNFα and D-dimer levels in any of these three
groups (data not shown).
Fetuin-A, CRP and TNFα levels of patients on
long-term prophylaxis did not differ from those of not
receiving it.
Discussion
To our best knowledge serum fetuin-A has not been inves-
tigated in patients with C1-INH-HAE. Compared to
healthy controls we observed significantly decreased serum
fetuin-A concentration levels in C1-INH-HAE patients.
This phenomenon cannot be explained by the negative
acute phase character of the molecule [11, 31] since CRP
and TNFα did increase accordingly. Our patients had no
documented infection at the time of HAE attacks. Since
fetuin-A levels did not correlate neither with the positive
acute phase protein CRP, nor with D-dimer or TNFα con-
centrations in any groups one might suppose that alter-
ation of fetuin-A level is independent of the acute phase
reaction.
Furthermore, TNFα levels in symptom-free C1-INH-HAE
patients were also found to be lower than in healthy con-
trols. Along with others [32] we found this phenomenon in
another patient cohort [33]. Demirtürk et al., however, ob-
served this only in type I C1-INH-HAE [32].
In theory danazol treatment could also cause lowering
of TNFα levels as it has been found in endometriosis
both in vitro and in vivo [16, 34]. This phenomenon has
not been observed in C1-INH-HAE.
Unexpectedly, serum fetuin-A levels were increased
significantly during the HAE attacks. This finding can be
explained by the several observations suggesting fetuin-A
plays an inhibitory role in inflammatory processes.
Fetuin-A acts as an inhibitor of neutrophil superoxide re-
lease [15] and is required for the spermine-induced
inhibition of TNFα release of macrophages [35]. Fetuin-A
proved to be a specific and potent inhibitor of
carrageenan-induced paw edema formation [36]. In accord
with this fetuin-A was shown to have a protective role in
experimentally induced cerebral ischaemia in rats [37]. This
effect was achieved by decrease of local TNFα production,
decrease of the infarct size (also associated with brain
edema). In addition, high mobility group box 1 (HMGB1), a
late-phase proinflammatory cytokine, which is released from
ischemic tissues and septic shock increases serum levels of
fetuin-A by 2–3-fold [37]. Along with TNFα and IL-1β,
HMGB1 also increases vascular permeability [38, 39].
Another explanation for the elevation of fetuin-A
levels during the HAE attacks can be linked to the acti-
vation of the contact-kinin system, the hallmark of HAE
attacks. There are interesting observations on the pos-
sible connection between the contact-kinin system and
fetuin-A. Bradykinin receptor 1 (BR1) knockout mice
have reduced fetuin-A concentration compared to wild
type [40]. Furthermore, these mice have lower insulin re-
sistance and are protected from non-alcoholic fatty liver
disease (NAFLD) after high fat diet treatment. Fetuin-A
is a well-known contributor to the development of insu-
lin resistance and NAFLD [21]. Thus it cannot be ruled
out that the activation of the contact-kinin system may
result in the upregulation of the fetuin-A synthesis.
These observations suggest that fetuin-A might have a
protective role in edema formation of C1-INH-HAE, as
well. The increase of serum fetuin-A levels can be ex-
plained by its augmented synthesis induced by the
damaged endothelium. The biological role of this
counter-regulatory action is to protect the endothelial
barrier function as it has been demonstrated in animal
experiments [36, 37].
In our study we found no significant changes in the
CRP levels of C1-INH-HAE patients. This finding is in
accord with that of Oshawa, who found normal CRP
levels in spite of leukocytosis even during abdominal at-
tacks [41]. Others found elevated CRP levels even in the
absence of an attack that increased further mainly in pa-
tients with abdominal localization [42]. They suppose
that this could be caused by the stimulatory effect
caused by translocation of bacterial LPS but the
CRP-rising effect of the edema formation itself cannot
Table 2 Comparison of serum fetuin-A, CRP and TNFα
concentrations in patients with C1-INH-HAE with different attack
localization
Symptom-free phase Attack p#
Subcutaneous attack (n = 12)
Fetuin-A, mg/l 254 (200–273) 295 (260–325) 0.033
CRP, mg/l 1.19 (0.99–6.16) 3.61 (0.79–4.44) 0.722
TNFα, ng/ml 2.19 (1.70–2.83) 2.73 (1.75–3.71) 0.237
D-dimer, μg/ml 0.52 (0.22–0.74) 1.15 (0.41–4.47) 0.110
Submucosal attack (n = 12)
Fetuin-A, mg/l 265 (241–297) 286 (262–320) 0.308
CRP, mg/l 1.84 (0.71–4.41) 3.64 (1.34–5.66) 0.272
TNFα, ng/ml 2.58 (1.11–2.88) 3.17 (1.80–4.75) 0.310
D-dimer, μg/ml 0.72 (0.17–2.19) 2.44 (1.07–16.52) 0.116
Values in median (25–75) percentiles
#Wilcoxon-test
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be ruled out, either [42]. In another series of our patient
group (n = 26) Veszeli et al. also found that CRP levels
were higher during the symptom-free period and, along
with true neutrophil activation, increased further during
HAE attacks [33]. Different timing of blood sampling
can also contribute to the differences in CRP levels in
C1-INH-HAE patients. Hofman et al. observed that the
rise of CRP occurred early in the attack (i.e., less than 5
h to 1 day) compared to later periods (7 and 22 days)
[42]. These findings are in contrast with our result, con-
sidering that blood samples were obtained from the pa-
tients within 6 h after the onset of the edematous
symptoms.
We confirmed that D-dimer levels increased during
HAE attacks which have been already described in the
literature [43–45].
Case-control design and the relatively small sample size
are limitations of our study. Moreover, nine patients were
on danazol. Chronic danazol treatment has been found to
decrease HDL-cholesterol and increase LDL-cholesterol
levels, respectively [46]. This might also be considered as
a confounding factor as there is a link between serum
fetuin-A levels and blood lipids. Long-term danazol
prophylaxis, however, does not deteriorate liver function
in patients with HAE [47].
In summary, we found decreased serum fetuin-A con-
centrations in patients with C1-INH-HAE, which signifi-
cantly rose during HAE attacks, characteristically in
subcutaneous localization. These changes cannot be ex-
plained by the negative acute phase character of
fetuin-A; rather by the anti-inflammatory characteristics
of the protein. Serum levels may not reflect effects of cy-
tokines at the cellular level. Clearly, large scale follow-up
studies on different C1-INH-HAE groups are needed to
elucidate the behavior and clinical usefulness of fetuin-A,
TNFα, and CRP concentrations in this disease.
Conclusions
Patients with C1-INH-HAE have decreased serum
fetuin-A concentrations during the symptom-free
period, which is probably not the consequence of the
acute phase reaction. Given the anti-inflammatory prop-
erties of fetuin-A, the increase of its levels during attacks
may contribute to the counter-regulation of edema for-
mation during C1-INH-HAE attacks.
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